WO2023203535A1 - 4-chromone derivatives as n-polymerase inhibitors for use in the treatment platinum resistant metastatic neoplasm - Google Patents
4-chromone derivatives as n-polymerase inhibitors for use in the treatment platinum resistant metastatic neoplasm Download PDFInfo
- Publication number
- WO2023203535A1 WO2023203535A1 PCT/IB2023/054098 IB2023054098W WO2023203535A1 WO 2023203535 A1 WO2023203535 A1 WO 2023203535A1 IB 2023054098 W IB2023054098 W IB 2023054098W WO 2023203535 A1 WO2023203535 A1 WO 2023203535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- compound
- mmol
- medical use
- gradient
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 16
- 229910052697 platinum Inorganic materials 0.000 title claims description 14
- 206010061289 metastatic neoplasm Diseases 0.000 title claims description 13
- 239000003112 inhibitor Substances 0.000 title description 6
- 150000004777 chromones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 134
- 239000000203 mixture Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- DGCOGZQDAXUUBY-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole Chemical compound C1=CC=C2OC(F)(F)OC2=C1 DGCOGZQDAXUUBY-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 229940127073 nucleoside analogue Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- -1 4-chromone derivative compounds Chemical class 0.000 abstract description 24
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 238000000034 method Methods 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000543 intermediate Substances 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 238000012512 characterization method Methods 0.000 description 27
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 27
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 16
- 239000000377 silicon dioxide Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- 239000012043 crude product Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001665 trituration Methods 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- UENLHUMCIOWYQN-UHFFFAOYSA-N 2'-Hydroxy-6'-methoxyacetophenone Chemical compound COC1=CC=CC(O)=C1C(C)=O UENLHUMCIOWYQN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 102100035481 DNA polymerase eta Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical compound C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VENJONDQZOOAHG-UHFFFAOYSA-N 1-(2-hydroxy-4,6-dimethoxyphenyl)pentan-1-one Chemical compound CCCCC(=O)C1=C(O)C=C(OC)C=C1OC VENJONDQZOOAHG-UHFFFAOYSA-N 0.000 description 1
- GGERGLKEDUUSAP-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2OC(F)(F)OC2=C1 GGERGLKEDUUSAP-UHFFFAOYSA-N 0.000 description 1
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- OGVPJBJWJCZBTH-UHFFFAOYSA-N 2-methyl-4-phenylmethoxybenzaldehyde Chemical compound C1=C(C=O)C(C)=CC(OCC=2C=CC=CC=2)=C1 OGVPJBJWJCZBTH-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- QFGRFXYRRKUUPV-UHFFFAOYSA-N 3,5-dihydroxychromen-4-one Chemical compound O1C=C(O)C(=O)C2=C1C=CC=C2O QFGRFXYRRKUUPV-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- YNPDEEPROJUWCY-UHFFFAOYSA-N 5-[[5-chloro-1-(naphthalen-2-ylmethyl)indol-3-yl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound ClC=1C=C2C(=CN(C2=CC=1)CC1=CC2=CC=CC=C2C=C1)C=C1C(NC(NC1=O)=S)=O YNPDEEPROJUWCY-UHFFFAOYSA-N 0.000 description 1
- QNYIZIMKWGODMU-UHFFFAOYSA-N 5-methoxy-4-oxochromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OC QNYIZIMKWGODMU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- VYUJSBAACMVZOJ-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)N1C(=O)NC(=O)C(C1=O)C=1NC2=CC=CC=C2C=1 Chemical compound C(C1=CC=CC=C1)(=O)N1C(=O)NC(=O)C(C1=O)C=1NC2=CC=CC=C2C=1 VYUJSBAACMVZOJ-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 108010093204 DNA polymerase theta Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001094607 Homo sapiens DNA polymerase eta Proteins 0.000 description 1
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AQIHMSVIAGNIDM-UHFFFAOYSA-N benzoyl bromide Chemical compound BrC(=O)C1=CC=CC=C1 AQIHMSVIAGNIDM-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000005621 boronate group Chemical class 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- OJRFUZPONYSMKF-UHFFFAOYSA-N ethyl 5-methoxy-4-oxochromene-2-carboxylate Chemical compound C1=CC=C2OC(C(=O)OCC)=CC(=O)C2=C1OC OJRFUZPONYSMKF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention applies to the medical field, and in particular for the treatment of tumors.
- DNA polymerases are enzymes involved in important cellular processes such as gene expression, regulation, transcription, and DNA damage repair.
- Y-Family Pols is an important group of enzymes capable of conducting the synthesis of translesion DNA (TLS): a biological process that involves the replication of damaged DNA, with good precision.
- TLS translesion DNA
- Such enzymes are capable of bypassing damaged bases, which would otherwise block the normal progression of the replication fork.
- Each Y-family polymerase is unique and has different "preferences" for lesions to bypass and for deoxyribonucleoside triphosphate (dNTP) to be incorporated.
- dNTP deoxyribonucleoside triphosphate
- DNA polymerase p (Pol) is capable of bypassing UV-induced cyclobutane pyrimidine (CPD) cis-syn dimers, suppressing the mutagenic effect of UV- induced DNA damage (Yang, 2014).
- CPD UV-induced cyclobutane pyrimidine
- Aurintricarboxylic acid and ellagic acid known inhibitors of Pol ⁇ , show very promising nanomolar IC50 values (Dorjsuren et al., 2009), but are characterized by poor selectivity and with an unspecific action mechanism that therefore limits the use thereof mainly to biological experiments only.
- N- benzoyl indolylbarbituric acid (ITBA) derivatives which show IC50s in the low micromolar range (Coggins et al., 2013) and act on the allosteric site of the enzyme.
- cisplatin and the analogues thereof react with DNA bases to cross-link adjacent purines.
- the inventors of the present patent application have surprisingly found that the compounds characterized by the general formula (I) can be employed for treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds.
- the present patent application describes compounds for medical use in treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds.
- such compounds are described for treating tumors in combination with other chemotherapeutic compounds.
- the present patent application describes a method for treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds comprising the administration of a pharmaceutically effective amount of a compound or formulation according to the invention. According to an even more particular aspect, such a method is carried out in association with other chemotherapeutic compounds.
- Figure 1 shows the structure of compounds known in the art.
- FIGS 2, 3 and 4 show Schemes 1, 2 and 3 mentioned in the present patent application, respectively.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are, independently of each other, -H, -OH, -R 7 , -x, -OR 7 , -R 7 (X)n, -NO 2 , -NH 2 , -NHR 7 , where
- R 7 is a linear or branched C 1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO 2 , -NH 2 , -NHR 8 , where R 8 is a linear or branched C 1-4 alkyl, or where
- A is preferably a single bond or, alternatively, is one of:
- the described compounds have the following formula: wherein
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are, independently of each other, -H, -OH, -R 7 , -X, -OR 7 , —R 7 (X) n , -NO 2 , -NH2, -NHR 7 , wherein
- R 7 is a linear or branched C 1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO 2 , -NH 2 , -NHR 8 , where R 8 is a linear or branched C 1-4 alkyl, or wherein
- R 1 , R 2 , R 3 , R 4 and R 7 are as described above and R 5 and R 6 form, together with the benzene ring to which they are bound, a (2,2- difluorobenzo[d][1,3]dioxol cycle: , and
- A is preferably a single bond or alternative
- the compounds above are described for medical use in the treatment of diseases or disorders associated with increased activity and/or expression of DNA polymerase ⁇ .
- Objects of the present invention are also prodrugs of the above compounds capable of increasing the bioavailability thereof in the body, such as boronates and hyaluronic acid polymers.
- neoplasms such as neoplasms. More in particular, such neoplasms are represented by primary and/or metastatic neoplasms.
- such a medical use is described for treating primary and/or metastatic neoplasms, which have developed resistance after a prior treatment with chemotherapeutic compounds.
- chemotherapeutics are represented by nucleoside analogs or alkylating agents derived from platinum, e.g., Cis platinum or analog compounds.
- neoplasms are represented by: ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric adenocarcinoma, mucosa-derived squamous cell carcinoma of the neck.
- the compounds of the present patent application are described for medical use in association with chemotherapeutic compounds.
- chemotherapeutic compounds are represented by nucleoside analogs or alkylating agents derived from platinum, such as Cis platinum or analog compounds, such as carboplatin or oxaliplatin.
- the compounds of the present patent application are described for medical use in association with other compounds having another mechanism of action, possibly in association with or as an alternative to radiotherapy.
- the compounds of the present patent application are described for medical use so as to avoid the occurrence of treatment resistance phenomena conducted against a primary and/or metastatic neoplasia.
- association means a not necessarily simultaneous therapeutic association, where the simultaneous association represents a preferred aspect.
- R 1 , R 2 , R 4 , R 5 and R 6 are, independently of each other, -H, -R 7 , -X, -OH, -OR 7 , -R 7 (X)n, -NO 2 , -NH 2 , -NHR 7 , wherein
- R 7 is a linear or branched C 1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO 2 , -NH 2 , -NHR 8 , where R 8 is a linear or branched C 1-4 alkyl,
- R 3 is H
- A is a single bond, provided that the compounds of formula (I) do not include:
- the compounds of formula (I) are represented by the following compounds:
- formulations comprising the compounds of the invention.
- Such formulations can be administered orally, nasally, subcutaneously or intramuscularly.
- such formulations comprise one or more pharmaceutically acceptable excipients being suitable for the route of administration.
- formulations of the invention are also described for the medical use and uses reported above.
- the present patent application describes a method for treating diseases or disorders associated with increased activity and/or expression of DNA polymerase p comprising administering a pharmaceutically effective amount of a compound or formulation according to the invention.
- neoplasms are represented by primary and/or metastatic neoplasms.
- such a method for treating primary and/or metastatic neoplasms, which have developed resistance after a prior treatment with chemotherapeutic compounds.
- chemotherapeutics are represented by nucleoside analogs or alkylating agents derived from platinum, e.g., Cis platinum or analog compounds.
- neoplasms are represented by: ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric adenocarcinoma, mucosa-derived squamous cell carcinoma of the
- the treatment method is described in association with chemotherapeutic compounds.
- chemotherapeutic compounds are represented by nucleoside analogs or alkylating agents derived from platinum, such as Cis platinum or analog compounds.
- the treatment method of the present patent application is described in association with other compounds having a different mechanism of action, possibly in association with or as an alternative to radiotherapy.
- the method of the present patent application is described to avoid the occurrence of treatment resistance phenomena conducted against a primary and/or metastatic neoplasia.
- association means a not necessarily simultaneous therapeutic association, where the simultaneous association represents a preferred aspect.
- the intermediates la and lb can be synthesized according to the procedure shown in European Journal of Medicinal Chemistry 180 (2019) 350-366.
- the intermediate 1c can be synthesized according to the procedure shown in prior art document WO 2017/132928 Al.
- the anhydrous solvents were purchased from Sigma-Aldrich.
- Spectra were acquired at 300 K, using deuterated dimethylsulfoxide (DMSO-d 6 ) or deuterated chloroform (CDCI 3 ) as solvents.
- DMSO-d 6 deuterated dimethylsulfoxide
- CDCI 3 deuterated chloroform
- UPLC/MS analyses were run on a Waters Acquity UPLC/MS system consisting of a SQD (single quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. The PDA range was 210-400 nm. The analyses were performed on an ACQUITY UPLC BEH C18 column (100x2.1 mmID, 1.7 pm particle size) with a VanGuard BEH C18 pre-column (5x2.1 mmID, 1.7 pm particle size).
- the mobile phase was 10 mM NH 4 OAC in H 2 O at pH 5 adjusted with CH 3 COOH (A) and 10 M NH 4 O C in CH 3 CN-H2O (95:5) at pH 5.0.
- Two types of gradients were applied depending on the analysis, gradient 1 (5% to 100% mobile phase B in 3 min) or gradient 2 (50% to 100% mobile phase B in 3 min).
- Electrospray ionization in positive and negative mode was applied.
- ESI was applied in positive and negative mode. All tested compounds showed ⁇ 95% purity by UPLC/MS analysis.
- the intermediate 3bb was prepared according to general procedure A described above using: ketone lb (200 mg, 1.00 mmol), 2,2- Difluoro-1,3-benzodioxol-5-carboxaldehyde 2b (210 g, 1.1 mmol), KOH (1680 mg, 20 mmol) in anhydrous MeOH (8.5 mL). The crude product was purified by trituration with EtOH (3 mL) to give the title intermediate 3bb (200 mg, 55% yield).
- the title compound 5df was prepared following general procedure D using: compound 4df (181 mg, 0.49 mmol), Pd/C (40 mg), Et 3 SiH (0.5 mL, 2.35 mmol) in a 1:1 mixture of MeOH/DCM (10 mL). Purification by silica (elution by gradient from 100 to 0 cyclohexane/EtOAc) gave the pure intermediate 5df (69 mg, 50% yield).
- Step 4 Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3- hydroxypropoxy)-4H-chromen-4-one (compound 9, Scheme 2).
- Compound 9 was prepared following general procedure D using: compound 8 (365 mg, 0.58 mmol), Pd/C (72 mg), Et 3 SiH (2.2 mL, 10.5 mmol) in a 1:1 mixture of MeOH/DCM (14 mL). Purification by silica (elution by gradient from 100 to 40/60 Cyclohexane/EtOAc) gave the pure compound 9 (33 mg, 15% yield in two steps).
- HATU (170 mg, 0.43 mmol) and DIPEA (0.23 mL, 1.3 mmol) were sequentially added to a solution of intermediate 11 (60 mg, 0.29 mmol) in a 3:1 mixture of DMF/DCM (4 mL) under argon.
- the reaction mixture was stirred at room temperature for 15 minutes, after that 3,4-dimethoxyaniline (44 mg, 0.29 mmol) was added and the reaction mixture was stirred for another 4 hours until complete consumption of the starting material.
- Compound 13 was prepared following general procedure C, method A using: intermediate 12 (45 mg, 0.13 mmol), BBrs (1 M in DCM) (0.59 mL, 0.59 mmol) in anhydrous CH2CI2 (2.6 mL). The crude product was purified by silica (elution by gradient from 100:0 to 98:2 DCM/MeOH) to give product 13 (0.016 g, 40% yield).
- Pol ⁇ activity was assessed by quantification of the final product of DNA synthesized with the enzyme in the presence of all four dNTPs/nucleotides.
- the double strand of DNA used in the reaction was created by annealing an IRD700-labeled primer to a template strand.
- a mixture of DNA template and Pol ⁇ was placed on ice in an assay buffer solution and then added in test tubes containing the inhibitors or DMSO (as vehicle; the final concentration in the assay is 1%).
- the reaction was started with the addition of 5 mM Mg 2+ and immediately transferred to 37°C. After 60 minutes of incubation, the reaction was stopped with the addition of 5X loading buffer for the sample and incubation for 5 minutes at 70°C.
- the Pol ⁇ extension products were then separated by denaturing electrophoresis (15% polyacrylamide/tbe/urea gel; BioRad) and scanned using the ChemiDoc imaging system (BioRad Laboratories).
- Compound 9 was evaluated for the inherent antiproliferative activity thereof, individually and together with cisplatin on the cancer cell lines A549, A375 and OVCAR3.
- the antiproliferative activity of compound 9 was evaluated using the MTT cell viability assay.
- the cells were seeded at a density of 5000 cells/well (A549), 3000 cells/well (A375) and 10000 cells/well (OVCAR3). After 24 hours, the cells were first treated with Cisplatin (0.4-50 ⁇ M) alone and compound 9 (0.046-100 ⁇ M), then with Cisplatin (0.4-50 ⁇ M) with compound 9 at 50 ⁇ M, 75 ⁇ M and 100 ⁇ M for 48 hours.
- the MTT solution was added to a final concentration of 0.5 mg/ml and the cells were further incubated for 4 hours.
- the insoluble formazan crystals were solubilized by the addition of a 10% 0.01 N SDS/HC1 solution and the absorbance measured at 570 nm (reference 690 nm) in a plate reader (Tecan Spark).
- the inhibition curves were 8 serial dilutions in triplicate in each case, and the results were analyzed as sigmoidal dose-response curves using GraphPad Prism software. The values are reported as meaniSD of three experiments. a The concentration of compound 9 is 100 ⁇ M b The concentration of compound 9 is 50 ⁇ M c The concentration of compound 9 is 75 ⁇ M
- the compounds described have been shown to be very active in inhibiting human polymerase eta (Pol ⁇ ) representing a potential tool for the therapy of chemo-resistant tumors in combination with current therapies, for example comprising the use of Cis platinum.
- the data obtained show the effectiveness in inhibiting the proliferation of cancer cells and the low cell toxicity.
- the main structure and substructures define scaffolds which allow a good chemical diversity, allowing many compounds with similar structure to be investigated.
- the compounds described are referred to as small molecules, thus being molecules of small size capable of being easily synthesized.
Abstract
The present invention relates to 4-chromone derivative compounds of general formula (I) and the medical use thereof as anticancer agents.
Description
4-CHROMONE DERIVATIVESAS N-POLYMERASE INHIBITORS FOR USE IN THETREATMENT PLATINUM RESISTANTMETASTATIC NEOPLASM
DESCRIPTION
The present invention applies to the medical field, and in particular for the treatment of tumors.
DNA polymerases (Pols) are enzymes involved in important cellular processes such as gene expression, regulation, transcription, and DNA damage repair.
Humans possess at least 16 different DNA polymerases, which are divided into families, each with different specific roles and functions.
In particular, Y-Family Pols is an important group of enzymes capable of conducting the synthesis of translesion DNA (TLS): a biological process that involves the replication of damaged DNA, with good precision.
Such enzymes are capable of bypassing damaged bases, which would otherwise block the normal progression of the replication fork.
Each Y-family polymerase is unique and has different "preferences" for lesions to bypass and for deoxyribonucleoside triphosphate (dNTP) to be incorporated.
In particular, among the Y-family polymerases, DNA polymerase p (Pol) is capable of bypassing UV-induced cyclobutane pyrimidine (CPD) cis-syn dimers, suppressing the mutagenic effect of UV- induced DNA damage (Yang, 2014).
In fact, genetic defects in the gene Pol η result in the development of a variant form of xeroderma pigmentosa (XPV) and
the patients are much more sensitive to sunlight and prone to developing skin cancer.
Aurintricarboxylic acid and ellagic acid, known inhibitors of Pol η, show very promising nanomolar IC50 values (Dorjsuren et al., 2009), but are characterized by poor selectivity and with an unspecific action mechanism that therefore limits the use thereof mainly to biological experiments only.
So far, the most potent class of Pol p inhibitors are N- benzoyl indolylbarbituric acid (ITBA) derivatives, which show IC50s in the low micromolar range (Coggins et al., 2013) and act on the allosteric site of the enzyme.
Nowadays, platinum-based drugs and nucleoside analogues are regularly prescribed in the treatment of cancer, and although they are effective, the use thereof is limited by inherent or acquired resistance.
Mechanically, cisplatin and the analogues thereof react with DNA bases to cross-link adjacent purines.
The preferential activation of DNA damage responses prevents replication fork collapse and promotes cell survival during chemotherapy treatment, leading to chemoresistance (Srivastava et al., 2015).
To date, there are no drugs for treating cancer in clinical practice and overcoming drug resistance to platinum-based drugs and nucleoside analogues.
Prior art document US 2010/0035887 describes poxvirus DNA polymerase inhibitor compounds.
International patent application WO 2006/076863 describes compounds having the general formula (I) shown in figure 1 having synergistic activity with anticancer agents such as cisplatin and/or 5-fluorouracil.
Prior art document "Synthesis, biological evaluation and SAR analysis of O-alkylated analogs of quercetin for anticancer" (Shi et al. Bioorganic & Medicinal Chemistry Letters 24 (2014) 4424- 4427) describes the synthesis of O-alkylated analogues of quercetin having anti-cancer activity. The general structure of such compounds is shown in figure 1.
Prior art document "A Small-Molecule Inhibitor of Human DNA Polymerase η Potentiates the Effects of Cisplatin in Tumor Cells." (Zafar et al. Biochemistry. 2018 February 20; 57(7): 1262-1273) describes the compound PNR-7-02, shown in figure 1, as a polymerase inhibitor. The same compound is described by WO 2006/076863 (WU YIXIN, China).
Prior art document WO 2019/008537 (Vera Salus Ricerca SRL, Italy) describes quercetin-derived compounds for medical use in the treatment of metastatic tumors and malignancies, depicted in figure 1.
Prior art document WO 2011/099978 (N30 Pharma. INC) describes flavone derivatives for treating cancer, tumors and metastatic neoplasms, depicted in figure 1.
Summary of the invention
The inventors of the present patent application have surprisingly found that the compounds characterized by the general formula (I) can be employed for treating diseases or disorders represented by
primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds.
Such an activity is completely unexpected based on the structure of similar compounds already known to have antiviral activity.
Object of the invention
In a first object, the present patent application describes compounds for medical use in treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds.
According to an even more particular aspect, such compounds are described for treating tumors in combination with other chemotherapeutic compounds.
In a second object, the present patent application describes compounds per se with the condition given in the following description.
In a third object, the present patent application describes pharmaceutical formulations comprising the compounds of the invention.
In another object, the present patent application describes a method for treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds comprising the administration of a pharmaceutically effective amount of a compound or formulation according to the invention.
According to an even more particular aspect, such a method is carried out in association with other chemotherapeutic compounds. Brief description of the drawings
Figure 1 shows the structure of compounds known in the art.
Figures 2, 3 and 4 show Schemes 1, 2 and 3 mentioned in the present patent application, respectively.
Detailed description of the invention
In accordance with a first object, compounds of formula (I) for medical use are described.
R1, R2, R3, R4, R5 and R6 are, independently of each other, -H, -OH, -R7, -x, -OR7, -R7(X)n, -NO2, -NH2, -NHR7, where
R7 is a linear or branched C1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO2, -NH2, -NHR8, where R8 is a linear or branched C1-4 alkyl, or where
R1, R2, R3, R4 and R7 are as described above and R5 and R6 form, together with the benzene ring to which they are bound, a (2,2- difluorobenzo[d][1,3]dioxol cycle:
, and
X is halogen in any position of the chain, n=1-4 on the entire chain and preferably 1-3 and
According to a preferred aspect of the present invention, the described compounds have the following formula:
wherein
R1, R2, R3, R4, R5 and R6 are, independently of each other, -H, -OH, -R7, -X, -OR7, —R7(X)n, -NO2, -NH2, -NHR7, wherein
R7 is a linear or branched C1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO2, -NH2, -NHR8, where R8 is a linear or branched C1-4 alkyl, or wherein
R1, R2, R3, R4 and R7 are as described above and R5 and R6 form, together with the benzene ring to which they are bound, a (2,2- difluorobenzo[d][1,3]dioxol cycle:
, and
X is halogen in any position of the chain,
n=1-4 on the entire chain and preferably 1-3 and
In accordance with an even more preferred aspect, the following compounds for medical use are described:
According to a particularly preferred aspect of the present invention, the following compounds for medical use are described:
According to an even more particularly preferred aspect, the following compounds for medical use are described:
For the purposes of the present invention, the compounds above are described for medical use in the treatment of diseases or disorders associated with increased activity and/or expression of DNA polymerase η.
Objects of the present invention are also prodrugs of the above compounds capable of increasing the bioavailability thereof in the body, such as boronates and hyaluronic acid polymers.
In particular, such a medical use is described for treating diseases or disorders associated with increased activity and/or expression of DNA polymerase p represented by neoplasms.
More in particular, such neoplasms are represented by primary and/or metastatic neoplasms.
According to a preferred aspect of the present invention, such a medical use is described for treating primary and/or metastatic neoplasms, which have developed resistance after a prior treatment with chemotherapeutic compounds.
In particular, for the purposes of the present invention, such chemotherapeutics are represented by nucleoside analogs or alkylating agents derived from platinum, e.g., Cis platinum or analog compounds.
In particular, such neoplasms are represented by: ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric adenocarcinoma, mucosa-derived squamous cell carcinoma of the neck.
In accordance with an aspect of the present invention, the compounds of the present patent application are described for medical use in association with chemotherapeutic compounds.
In particular, such chemotherapeutic compounds are represented by nucleoside analogs or alkylating agents derived from platinum, such as Cis platinum or analog compounds, such as carboplatin or oxaliplatin.
According to an alternative aspect, the compounds of the present patent application are described for medical use in association with other compounds having another mechanism of action, possibly in association with or as an alternative to radiotherapy.
In an aspect of the invention, the compounds of the present patent application are described for medical use so as to avoid the occurrence of treatment resistance phenomena conducted against a primary and/or metastatic neoplasia.
For the purposes of the present invention, the term "in association" means a not necessarily simultaneous therapeutic association, where the simultaneous association represents a preferred aspect.
R1, R2, R4, R5 and R6 are, independently of each other, -H, -R7, -X, -OH, -OR7, -R7(X)n, -NO2, -NH2, -NHR7, wherein
R7 is a linear or branched C1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO2, -NH2, -NHR8, where R8 is a linear or branched C1-4 alkyl,
R3 is H,
X is halogen in any position of the chain, n=1-4 on the entire chain and preferably 1-3 and
A is a single bond, provided that the compounds of formula (I) do not include:
According to an even more preferred aspect, the compounds of formula (I) are represented by the following compounds:
In accordance with a second object, the present patent application describes formulations comprising the compounds of the invention.
Such formulations can be administered orally, nasally, subcutaneously or intramuscularly.
In particular, such formulations comprise one or more pharmaceutically acceptable excipients being suitable for the route of administration.
According to a particular aspect, the formulations of the invention are also described for the medical use and uses reported above.
In accordance with another object, the present patent application describes a method for treating diseases or disorders associated with increased activity and/or expression of DNA polymerase p comprising administering a pharmaceutically effective amount of a compound or formulation according to the invention.
More in particular, such neoplasms are represented by primary and/or metastatic neoplasms.
According to a preferred aspect of the present invention, such a method is described for treating primary and/or metastatic neoplasms, which have developed resistance after a prior treatment with chemotherapeutic compounds.
In particular, for the purposes of the present invention, such chemotherapeutics are represented by nucleoside analogs or alkylating agents derived from platinum, e.g., Cis platinum or analog compounds.
In particular, such neoplasms are represented by: ovarian cancer, breast cancer, pancreatic cancer, lung cancer, gastric adenocarcinoma, mucosa-derived squamous cell carcinoma of the
In accordance with an aspect of the present invention, the treatment method is described in association with chemotherapeutic compounds.
In particular, such chemotherapeutic compounds are represented by nucleoside analogs or alkylating agents derived from platinum, such as Cis platinum or analog compounds.
According to an alternative aspect, the treatment method of the present patent application is described in association with other compounds having a different mechanism of action, possibly in association with or as an alternative to radiotherapy.
In an aspect of the invention, the method of the present patent application is described to avoid the occurrence of treatment resistance phenomena conducted against a primary and/or metastatic neoplasia.
For the purposes of the present invention, the term "in association" means a not necessarily simultaneous therapeutic association, where the simultaneous association represents a preferred aspect.
The present invention is further described in the following experimental section.
Experimental section
Synthesis - General considerations
All the commercially available reagents and solvents were used as purchased from vendors without further purification. The intermediates la and lb can be synthesized according to the procedure shown in European Journal of Medicinal Chemistry 180
(2019) 350-366. The intermediate 1c can be synthesized according to the procedure shown in prior art document WO 2017/132928 Al. The anhydrous solvents were purchased from Sigma-Aldrich. Automated column chromatography purifications were done using a Teledyne ISCO apparatus (CombiFlash® Rf) with pre-packed silica gel columns of different sizes (from 4 g up to 120 g) and mixtures of increasing polarity of cyclohexane and ethyl acetate (EtOAc) or dichloromethane (DCM) and methanol (MeOH). NMR experiments were run on a Bruker Avance III 400 system (400.13 MHz for 1H, and 100.62 MHz for 13C), equipped with a BBI probe and Z-gradients. Spectra were acquired at 300 K, using deuterated dimethylsulfoxide (DMSO-d6) or deuterated chloroform (CDCI3) as solvents. For 1H-NMR, data are shown as follows: chemical shift, multiplicity (s= singlet, d= doublet, dd= double of doublets, ddd= doublet of doublet of doublets, t= triplet, td= triplet of doublets, q= quartet, p= quintet, m= multiplet), coupling constants (Hz) and integration. UPLC/MS analyses were run on a Waters Acquity UPLC/MS system consisting of a SQD (single quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. The PDA range was 210-400 nm. The analyses were performed on an ACQUITY UPLC BEH C18 column (100x2.1 mmID, 1.7 pm particle size) with a VanGuard BEH C18 pre-column (5x2.1 mmID, 1.7 pm particle size). The mobile phase was 10 mM NH4OAC in H2O at pH 5 adjusted with CH3COOH (A) and 10 M NH4O C in CH3CN-H2O (95:5) at pH 5.0. Two types of gradients were applied depending on the analysis, gradient 1 (5% to 100% mobile phase B in 3 min) or gradient 2 (50% to 100% mobile phase B in 3 min).
Electrospray ionization in positive and negative mode was applied. ESI was applied in positive and negative mode. All tested compounds showed ≥ 95% purity by UPLC/MS analysis.
General procedure A. Aldol condensation (Scheme 1).
The appropriate ketone of type 1 (1.0 eq.) and benzaldehyde of type 2 (1.1 eq) were added to a solution of potassium hydroxide (20.0 eq.) in MeOH (0.12 M). The reaction mixture was stirred at room temperature. After complete conversion of starting materials, the reaction mixture was acidified to pH=5 with 1 M HC1 and extracted with EtOAc (3x5 mL). Combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum. The product was purified by flash chromatography or trituration with EtOH giving the pure intermediate of type 3.
General procedure B. Oxidative cyclization (Scheme 1).
The appropriate chaicone of type 3 (1 eq.) was dissolved in DMSO (0.3 M) and heated at 135°C under argon atmosphere. I2 (0.05 eq.) was added and the reaction mixture was stirred until full conversion of the starting material. After reaction completion, the reaction mixture was cooled to room temperature and sodium thiosulfate 1 N was added to quench iodine. The crude product was filtered, washed with water and purified by flash chromatography giving the pure compound of type 4.
General procedure C. Methyl deprotection (Scheme 1).
Method A.
The appropriate compound of type 4 (1 eq.) was treated with pyridinium chloride (10 eq.) and the reaction mixture was heated at 190°C under argon atmosphere until total conversion of the
starting material. After reaction completion, the reaction mixture was cooled down to room temperature and added with water. The crude product was filtered, washed with water and purified by silica.
Method B.
The appropriate compound of type 4 (1 eq.) was dissolved in DCM (0.05 M) and cooled to 0°C. A IM solution of boron tribromide in DCM (1.5 eq for each methoxy group) was added and the reaction mixture was allowed to warm to room temperature and stirred until complete conversion of the starting material under argon atmosphere. After reaction completion, the reaction was quenched with MeOH and concentrated under reduced pressure. The crude product was redissolved in MeOH, concentrated under vacuum and purified by flash chromatography.
General Procedure D. Benzyl deprotection (Scheme 1, 2)
An appropriate benzylated compound was dissolved in a 1:1 mixture MeOH/DCM (0.04 M) under an argon atmosphere. Pd/C (20% w/w) triethylsilane (6 eq. for each benzyl group) were added to the solution. The reaction mixture was stirred at 40°C until complete conversion of the starting material. Then, the reaction mixture was filtered over a bed of celite and concentrated under vacuum. The crude product was taken up in ethyl acetate and the organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated under vacuum, and purified by silica.
Synthesis of 2- (3,4-dihydroxyphenyl)-5,7-dihydroxy-3-propy1-4H- chromen-4-one (compound 5aa, Scheme 1).
Step 1. Synthesis of (E)-2-(3,4-dimethoxybenzylidene)-1-(2- hydroxy-4,6-dimethoxyphenyl)pentane-1-one (Intermediate 3aa, Scheme 1)
The title compound was synthesized following the general procedure A described above using 1-(2-hydroxy-4,6-dimethoxyphenyl)pentane-1-one la (105 mg, 0.60 mmol), 3,4-dimethoxybenzaldehyde 2a (101 mg, 0.66 mmol) and potassium hydroxide (675 mg, 12 mmol) in MeOH (5 mL). Purification by silica (elution by gradient from 100 to 70/30 cyclohexane/EtOAc) gave the pure intermediate 3aa (116 mg, 50% yield).
Characterization: UPLC/MS Rt: 2.40 min (gradient 1), MS (ESI) m/z: 387.2 [M+H]+ .[M+H]+ Calculated for C22H27O6: 387.2. 1H-NMR (400 MHz,
DMSO-d6) δ 9.70 (s, 1H), 7.04 (s, 1H), 7.01 (d, J = 8.1 Hz, 1H),
6.97 - 6.89 (m, 2H), 6.12 (d, J = 2.1 Hz, 1H), 6.07 (d, J = 2.1
Hz, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.74 (s, 3H), 3.65 (s, 3H), 1.57 - 1.44 (m, 2H), 1.17 (t, J = 7.1 Hz, 2H), 0.96 (t, J = 7.3
Hz, 3H).
Step 2, Synthesis of 2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-3- propy1-4H-chromen-4-one (Intermediate 4aa, Scheme 1).
The title compound was synthesized following the general procedure B described above using intermediate 3aa (116 mg, 0.3 mmol) and I2 (4 mg, 0.01 mmol) in DMSO (1 mL). Purification by silica (elution by gradient from 15/85 to 50/50 cyclohexane/EtOAc) gave the pure intermediate 4aa (54 mg, 50% yield).
Characterization: UPLC/MS Rt: 2.23 min (gradient 1), MS (ESI) m/z: 385.2 [M+H]+.[M+H]+ Calculated for C22H25O6: 385.2. 1H-NMR (400 MHz, DMSO-d6) δ 7.20 - 7.15 (m, 2H), 7.12 (s, 1H), 6.64 (d, J = 2.3 Hz, 1H), 6.48 (d, J = 2.3 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H), 2.38 - 2.29 (m, 2H), 1.53 - 1.39 (m, 2H), 0.82 (t, J = 7.3 Hz, 3H).
Step 3. Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3- propy1-4H-chromen-4-one (compound 5aa, Scheme 1).
The title compound was synthesized following the general procedure
C Method A described above using intermediate 4aa (54 mg, 0.14
mmol) and pyridinium chloride (162 mg, 1.4 mmol). Purification by silica (elution by gradient from 100 to 94:6 DCM/MeOH) gave the pure compound 5aa (35 mg, 76% yield).
Characterization: UPLC/MS Rt: 1.93 min (gradient 1), MS (ESI) m/z: 329.3 [M+H]+ .[M+H]+ Calculated for C18H17O6: 329.1. 1H-NMR (400 MHz, DMSO-d6) δ 13.08 (s, 1H), 7.01 (d, J = 2.1 Hz, 1H) 6.93 (dd, J = 8.2, 2.1 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.28 (d, J = 2.1 Hz, 1H), 6.16 (d, J = 2.1 Hz, 1H), 2.44 - 2.35 (m, 2H), 1.56 - 1.42 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C-NMR (101 MHz, DMSO-d6) δ 182.20, 164.66, 162.78, 161.93, 157.77, 148.25, 145.67, 123.83,
120.86, 118.66, 116.21, 116.02, 103.53, 99.01, 93.77, 27.07,
22.25, 14.53.
Synthesis of 2-(3,4-dihydroxyphenyl)-7-fluoro-5-hydroxy-4H- chromen-4-one (compound 5ca, Scheme 1).
Step 1. Synthesis of (E)-3-(3,4-dimethoxyphenyl)-1-(4-fluoro-2- hydroxy-6-methoxyphenyl)prop-2-en-1-one (compound 3ca, Scheme 1).
The title compound was synthesized following the general procedure
A described above using: ketone lc (150 mg, 0.46 mmol), 3,4- dimethoxybenzaldehyde 2a (84 mg, 0.51 mmol), KOH (515 mg, 9.2 mmol) in anhydrous MeOH (3.9 mL). The crude product was purified
by trituration with EtOH (1.5 mL) to give the title intermediate 3ca (120 mg, 92% yield).
Characterization: UPLC/MS Rt = 2.47 min (gradient 1), MS (ESI) m/z 333.5, [M+H]+ . [M+H]+ calculated for C18H18FO5: 333.3. 1H NMR (400
MHz, CDC13) δ 13.90 (d, J = 1.4 Hz, 1H), 7.81 (d, J = 15.5 Hz,
1H), 7.72 (d, J = 15.5 Hz, 1H), 7.23 (dd, J = 8.3, 2.0 Hz, 1H),
7.13 (d, J = 2.0 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.32 (dd, J =
10.1, 2.4 Hz, 1H), 6.16 (dd, J = 11.0, 2.4 Hz, 1H), 3.95 (s, 3H),
3.94 (s, 3H), 3.94 (s, 3H).
Step 2, Synthesis of 2-(3,4-dimethoxyphenyl)-7-fluoro-5-methoxy- 4H-chromen-4-one (compound 4ca, Scheme 1).
Intermediate 4ca was prepared according to general procedure B described above using: Intermediate 3ca (150 mg, 0.45 mmol), I2 (6 mg, 0.02 mmol) in anhydrous DMSO (1.5 mL). The crude product was purified by trituration with EtOH (1 mL) to give the title intermediate 4ca (120 mg, 80% yield).
Characterization: UPLC/MS Rt = 1.93 min (gradient 1), MS (ESI) m/z 331.1, [M+H]+ . [M+H]+ calculated for C18H16FO5: 331.3. 1H NMR (400
MHz, CDCI3) δ 7.50 (dd, J = 8.5, 2.2 Hz, 1H), 7.31 (d, J = 2.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.82 (dd, J = 9.0, 2.4 Hz, 1H),
6.64 (s, 1H), 6.57 (dd, J = 11.1, 2.4 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 3.95 (s, 3H).
Step 3. Synthesis of 2-(3,4-dihydroxyphenyl)-7-fluoro-5-hydroxy-
The title compound was prepared according to general procedure C, Method B described above using: intermediate 4ca (100 mg, 0.30 mmol), 1 M BBr3 in DCM (1.4 mL, 1.4 mmol) in anhydrous DCM (6 mL). Crystallization from EtOH (1.5 mL) gave the pure compound 5ca (56 mg, 66% yield).
Characterization: UPLC/MS Rt = 1.99 min (gradient 1), MS (ESI) m/z 287.1, [M-H]-. [M-H]- calculated for C15H8FO5: 287.2.
NMR (400 MHz, DMSO-d6) δ 13.24 (s, 1H), 7.47 (dd, J = 8.4, 2.3 Hz, 1H), 7.44
(d, J = 2.3 Hz, 1H), 7.08 (dd, J = 10.0, 2.4 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.84 (s, 1H), 6.72 (dd, J = 10.9, 2.3 Hz, 1H).
Synthesis of 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7- methoxy-4H-chromen-4-one (compound 5.1bb, Scheme 1).
Step 1. Synthesis of (E)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)- 1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one) (intermediate 3bb, Scheme 1).
The intermediate 3bb was prepared according to general procedure A described above using: ketone lb (200 mg, 1.00 mmol), 2,2- Difluoro-1,3-benzodioxol-5-carboxaldehyde 2b (210 g, 1.1 mmol), KOH (1680 mg, 20 mmol) in anhydrous MeOH (8.5 mL). The crude product was purified by trituration with EtOH (3 mL) to give the title intermediate 3bb (200 mg, 55% yield).
Characterization: UPLC/MS Rt = 1.98 min (gradient 1), MS (ESI) m/z 365.0, [M+H]+ . [M+H]+ calculated for C18H15F2O6: 365.3. 1H NMR (400
MHz, CDCI3) δ 14.19 (s, 1H), 7.79 (d, J = 15.5 Hz, 1H), 7.70 (d, J = 15.6 Hz, 1H), 7.32 (d, J = 1.6 Hz, 1H), 7.30 (dd, J = 8.8, 1.7 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 6.11 (d, J = 2.3 Hz, 1H), 5.97 (d, J = 2.4 Hz, 1H), 3.92 (s, 3H), 3.84 (s, 3H).
Step 2. Synthesis of intermediate n (2-(2,2- difluorobenzo[d][1,3]dioxol-5-yl)-5,7-dimethoxy-4H-chromen-4-one) (compound 4bb).
Intermediate 4bb was prepared according to general procedure B described above using: intermediate 3bb (180 mg, 0.51 mmol), I2 (6.4 mg, 0.02 mmol) in anhydrous DMSO (1.7 mL). The crude product
was purified by trituration with EtOH (1 mL) to give the title compound 4bb (140 mg, 79% yield).
Characterization: UPLC/MS Rt = 1.06 min (gradient 2), MS (ESI) m/z 363.1, [M+H]+ . [M+H]+ calculated for C18H13F2O6: 363.3. 1H NMR (400
MHz, CDCl3) δ 7.64 (dd, J = 8.4, 1.8 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 0.9 Hz, 1H), 6.55 (d, J = 2.2 Hz, 1H), 6.38 (d, J = 2.3 Hz, 1H), 3.95 (s, 3H), 3.91 (s, 3H).
Step 3. Synthesis of 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-5- hydroxy-7-methoxy-4H-chromen-4-one (compound 5.1bb, Scheme 1).
Compound 5.lbb was prepared according to general procedure C, Method B described above using: intermediate 4bb (100 mg, 0.28 mmol), 1 MBBr3 in CH2CI2 (0.42 mL, 0.42 mmol) in anhydrous CH2CI2 (10 mL). Crystallization from EtOH (1.5 mL) gave the pure compound 5.lbb (56 mg, 57% yield).
Characterization: UPLC/MS Rt = 2.67 min (gradient 1), MS (ESI) m/z 247.0, [M-H]-. [M-H]- calculated for C17H9F2O6: 347.3. 1H NMR (400
MHz, DMSO-d6) δ 7.44 (dd, J = 8.3, 2.3 Hz, 1H), 7.41 (d, J = 2.3 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 6.70 (s, 1H), 6.37 (d, J = 2.2 Hz, 1H), 3.87 (s, 3H).
Synthesis of 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-5,7- dihydroxy-4H-chromen-4-one (compound 5.2bb, Scheme 1).
Compound 5.2bb was prepared according to general procedure C method A using: intermediate 4bb (100 mg, 0.28 mmol), pyridinium chloride (324, 2.8 mmol). Crystallization with EtOH (1.5 mL) gave the pure compound 5.2bb (28 mg, 30% yield).
Characterization: UPLC/MS Rt = 2.28 min (gradient 1), MS (ESI) m/z 333.1,
calculated for C16H7F2O6: 333.2. 1H NMR (400
MHz, DMSO) δ 12.71 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 8.6, 1.8 Hz, 1H), 7.57 (d, J = 8.6 Hz, 1H), 6.96 (s, 1H), 6.51 (d, J = 2.1 Hz, 1H), 6.19 (d, J = 2.1 Hz, 1H).
Synthesis of 5-methoxy-2-(or—tolyl)-4H-chromen-4-one (compound 4dc, Scheme 1).
Step 1. Synthesis of (E)-1-(2-hydroxy-6-methoxy-phenyl)-3-(or- tolyl)prop-2-en-1-one (compound 3dc, Scheme 1).
The title compound was synthesized following general procedure A using 1-(2-hydroxy-6-methoxyphenyl)ethan-1-one Id (100 mg, 0.60 mmol), 2-methylbenzaldehyde 2c (0.08 mL, 0.66 mmol) and potassium hydroxide (675 mg, 12 mmol) in MeOH (5 mL). Purification by silica
(elution by gradient from 100 to 95/5 cyclohexane/EtOAc) gave the pure intermediate 3dc (118 mg, 73% yield).
Characterization: UPLC/MS Rt: 2.60 min (gradient 1), MS (ESI) m/z: 269.1 [M+H]+ .[M+H]+ Calculated for C17H17O3: 269.1. 1H-NMR (400 MHz, CDC13) δ 13.15 (s, 1H), 8.11 (d, J = 15.5 Hz, 1H), 7.79 (d, J =
15.5 Hz, 1H), 7.69 - 7.62 (m, 1H), 7.37 (dd like t, J = 8.3 Hz,
1H), 7.33 - 7.21 (m, 3H), 6.62 (d, J = 8.3 Hz, 1H), 6.44 (d, J =
8.3 Hz, 1H), 3.95 (s, 3H), 2.51 (s, 3H).
The title compound was synthesized following general procedure B using compound 3dc (118 mg, 0.70 mmol) and I2 (8 mg, 0.03 mmol) in DMSO (1 mL). Purification by silica (elution by gradient from 100 to 50/50 cyclohexane/EtOAc) gave the pure intermediate 4dc (79 mg, 75% yield).
Characterization: UPLC MS Rt: 2.01 min (gradient 1), MS (ESI) m/z: 267.1 [M+H]+ .[M+H]+ Calculated for C17H15O3: 267.1. 1H-NMR (400 MHz, DMSO-d6) δ 7.69 (dd like t, J = 8.4 Hz, 1H), 7.59 (dd, J = 7.7, 1.4 Hz, 1H), 7.46 (ddd like td, J = 7.5, 1.4 Hz, 1H), 7.41 - 7.31 (m, 2H), 7.18 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 6.33 (s,
1H), 3.87 (s, 3H), 2.43 (s, 3H).
13C-NMR (101 MHz, DMSO-d6) δ 176.24, 162.79, 159.21, 157.84,
136.42, 134.35, 131.77, 131.12, 130.70, 129.13, 126.26, 113.64, 112.69, 109.91, 107.29, 56.18, 20.12.
Synthesis of 2-(2-fluorophenyl)-5-methoxy-4H-chromen-4-one
(compound 4dd, Scheme 1)
Step 1. Synthesis of (E)-3-(2-fluorophenyl)-1-(2-hydroxy-6- methoxyphenyl)prop-2-en-1-one (compound 3dd, Scheme 1).
The title compound was synthesized following general procedure A using ketone Id (100 mg, 0.60 mmol), 2-fluorobenzaldehyde 2d (82.0 mg, 0.66 mmol) and KOH (675 mg, 12 mmol) in MeOH (5 mL). Trituration with EtOH gave the pure compound 3dd (96 mg, 59% yield).
Characterization: UPLC/MS Rt: 2.52 min (gradient 1), MS (ESI) m/z: 273.1 [M+H]+ .[M+H]+ Calculated for C16H14FO3: 273.1. 1H-NMR (400 MHz, CDCI3) δ 13.10 (s, 1H), 7.98 (d, J = 15.8 Hz, 1H), 7.88 (d, J =
15.8 Hz, 1H), 7.61 (ddd like td, J = 7.6, 1.8 Hz, 1H), 7.42 - 7.32
(m, 2H), 7.19 (ddd like td, J = 7.5, 1.1 Hz, 1H), 7.15 (d, J = 1.1
Hz, 1H), 6.62 (dd, J = 8.4, 1.0 Hz, 1H), 6.44 (dd, J = 8.4, 1.0
Hz, 1H), 3.95 (s, 3H).
Step 2. Synthesis of 2-(2-fluorophenyl)-5-methoxy-4H-chromen-4-one
(compound 4dd, Scheme 1).
The title compound was synthesized following general procedure B using intermediate 3dd (96 mg, 0.40 mmol) and I2 (5 mg, 0.02 mmol) in DMSO (1 mL). Purification by silica (elution by gradient from 100 to 50/50 Cyclohexane/EtOAc) gave the pure compound 4dd (79 mg, 63% yield).
Characterization: UPLC/MS Rt: 1.96 min (gradient 1), MS (ESI) m/z: 271.1 [M+H]+.[M+H]+ Calculated for C16H12FO3: 271.1. 1H-NMR (400 MHz, DMSO-d6) δ 8.01 (ddd like td, J = 7.9, 1.8 Hz, 1H), 7.72 (dd like t, J = 8.4 Hz, 1H), 7.68 - 7.62 (m, 1H), 7.49 - 7.39 (m, 2H), 7.24 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.61 (s, 1H), 3.87 (s, 3H).
Synthesis of 5-methoxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4- one (compound 4de, Scheme 1)
Step 1. Synthesis of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(2-
(trifluoromethyl)phenyl)prop-2-en-1-one (intermediate 3de, Scheme
1)-
The title compound was synthesized following general procedure A using ketone Id (100 mg, 0.60 mmol), 2- (trifluoromethyl)benzaldehyde 2e (0.09 mL, 0.66 mmol) and KOH (675 mg, 12 mmol) in MeOH (5 mL). Trituration with EtOH gave the pure compound 3de (126 mg, 65% yield).
Characterization: UPLC/MS Rt: 2.64 min (gradient 1), MS (ESI) m/z: 323.1 [M+H]+ .[M+H]+ Calculated for C17H14F3O3: 323.1. 1H-NMR (400
MHz, CDCI3) δ 13.01 (s, 1H), 8.17 - 8.07 (m, 1H), 7.81 (d, J = 1.9 Hz, 1H), 7.78 (d, J = 6.0 Hz, 1H), 7.76 - 7.70 (m, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.38 (t, J = 8.3 Hz, 1H), 6.63 (dd, J = 8.4, 1.0 Hz, 1H), 6.43 (dd, J = 8.3, 1.0 Hz, 1H), 3.94 (s, 3H).
Step 2. Synthesis of 5-methoxy-2-(2-(trifluoromethyl)phenyl)-4H- chromen-4-one (compound 4de, Scheme 5).
The title compound was synthesized following general procedure B using intermediate 3de (126 mg, 0.35 mmol) and I2 (5 mg, 0.02 mmol) in DMSO (1 mL). Purification by silica (elution by gradient from 100 to 94/6 DCM/MeOH) gave the pure compound 4de (108 mg, 84% yield).
Characterization: UPLC/MS Rt: 2.13 min (gradient 1), MS (ESI) m/z: 321.1 [M+H]+ .[M+H]+ Calculated for C17H12F3O: 321.1. 1H-NMR (400 MHz,
DMSO-d6) 6 8.00 - 7.93 (m, 1H), 7.89 - 7.77 (m, 3H), 7.71 (dd like t, J = 8.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 3.88 (s, 3H).
Synthesis of 2-(4-hydroxy-2-methylphenyl)-5-methoxy-4H-chromen-4- one (compound 5df, Scheme 1).
Step 1. Synthesis of (E)-3-(4-benzyloxy)-2-methoxyphenyl)-1-(2- hydroxy-6-methoxyphenyl)prop-2-en-1-one (compound 3df, Scheme 1)
The title compound was synthesized following general procedure A using ketone Id (100 mg, 0.60 mmol), 4-benzyloxy-2-methyl- benzaldehyde 2f (149 mL, 0.66 mmol) and KOH (675 mg, 12 mmol) in MeOH (5 mL). The crude product was triturated with MeOH to give pure compound 3df (224 mg, quantitative yield).
Characterization: UPLC/MS Rt: 2.21 min (gradient 2), MS (ESI) m/z: 375.1 [M+H]+ .[M+H]+ Calculated for C24H23O4: 375.1. 1H-NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 8.6 Hz, 1H), 7.58 (d, J = 15.8 Hz, 1H), 7.48 - 7.30 (m, 5H), 7.26 (dd like t, J = 8.3 Hz, 1H), 7.01 (d, J = 15.8 Hz, 1H), 6.97 - 6.85 (m, 2H), 6.63 - 6.47 (m, 2H), 5.14 (s, 2H), 3.75 (s, 3H), 2.27 (s, 3H).
Step 2. Synthesis of 2-(4-benzyloxy)-2-methylphenyl)-5-methoxy-4H- chromen-4-one (compound 4df, Scheme 1).
The title compound was synthesized following general procedure B using intermediate 3df (224 mg, 0.59 mmol), I2 (7 mg, 0.03 mmol) in DMSO (1 mL). Purification by silica (elution by gradient from 100 to 20/80 Cyclohexane/EtOAc) gave the pure compound 4df (181 mg, 83% yield).
Characterization: UPLC/MS Rt: 1.39 min (gradient 1), MS (ESI) m/z: 373.1 [M+H]+ .[M+H]+ Calculated for C24H21O4: 373.1. 1H-NMR (400 MHz, DMSO-da) δ 7.67 (dd like t, J = 8.4 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.49 - 7.44 (m, 2H), 7.44 - 7.37 (m, 2H), 7.37 - 7.30 (m, 1H), 7.16 (dd, J = 8.5, 0.9 Hz, 1H), 7.05 (d, J = 2.6 Hz, 1H), 7.02 - 6.95 (m, 2H), 6.28 (s, 1H), 5.18 (s, 2H), 3.87 (s, 3H), 2.43 (s, 3H).
Step 3. Synthesis of 2-(4-hydroxy-2-methylphenyl)-5-methoxy-4H- chromen-4-one (compound 5df, Scheme 1).
The title compound 5df was prepared following general procedure D using: compound 4df (181 mg, 0.49 mmol), Pd/C (40 mg), Et3SiH (0.5
mL, 2.35 mmol) in a 1:1 mixture of MeOH/DCM (10 mL). Purification by silica (elution by gradient from 100 to 0 cyclohexane/EtOAc) gave the pure intermediate 5df (69 mg, 50% yield).
Characterization: UPLC/MS Rt: 1.64 min (gradient 1), m/z: 283.1 [M+H]+ .[M+H]+ Calculated for C17H15O4: 283.1. 1H-NMR (400 MHz, DMSO- d6) δ 7.66 (dd like t, J = 8.4 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.15 (dd, J = 8.4, 0.9 Hz, 1H), 6.98 (dd, J = 8.4, 0.9 Hz, 1H), 6.77 - 6.68 (m, 2H), 6.23 (s, 1H), 3.86 (s, 3H), 2.38 (s, 3H). Reference is now made to Scheme 2 in figure 3.
Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3- hydroxypropoxy)-4H-chromen-4-one (compound 9, Scheme 2).
Step 1. Synthesis of 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5- hydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
((((2R,3R,4R,5R,6S) -3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-
To a solution of rutin (2000 mg, 2.96 mmol) in DMF (20 mL) K2CO3 (1716 mg, 12.44 mmol) and benzoyl bromide (2.8 mL, 23.68 mmol) were added. The reaction mixture was stirred overnight at room temperature. Then it was diluted with EtOAc (60 mL). The organic
phase was divided, washed with water (2x50 mL), dried over magnesium sulfate, filtered and concentrated under vacuum giving the crude product 6, which was used without further purification for the next step (2000 mg).
Characterization: UPLC/MSRt: 2.44 min (gradient 1), MS (ESI) m/z: 881.3 [M+H]+ .[M+H]+ Calculated for C48H49O16: 883.3.
Step 2. Synthesis of 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-
Intermediate 6 (2000 mg, 2.27 mmol) was dissolved in EtOH (14 mL) to which 37% HC1 (2 mL) was added. The reaction mixture was refluxed for 120 minutes. After complete conversion of the starting material, the reaction mixture was cooled to room temperature and filtered. The precipitate was washed with water (5 mL) and cold MeOH (5 mL), giving the pure product 7 (1394 mg, yield: 82% in the two steps).
Characterization: UPLC/MS Rt: 2.55 min (gradient 2), MS (ESI) m/z: 573.2 [M+H]+ .[M+H]+ Calculated for C36H29O7: 573.2. 1H-NMR (400 MHz, DMSO-d6) δ 11.70 (s, 1H), 7.85 (d, J = 2.1 Hz, 1H), 777 (dd, J =
8.5, 2.0 Hz, 1H), 7.54 - 7.29 (m, 16H), 7.04 (d, J = 8.7 Hz, 1H),
6.52 (d, J = 2.2 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 5.25 (s, 4H),
5.15 (s, 2H).
Step 3. Synthesis of 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5- hydroxy-3-(3-hydroxypropoxy)-4H-chromen-4-one (compound 8, Scheme
2).
K2CO3 (248 mg, 0.18 mmol) and 3-bromo-1-propanol (0.14 mL, 0.9 mmol) were added to a solution of intermediate 8 (350 mg, 0.60 mmol) in DMF (10 mL) and the reaction mixture was stirred under argon atmosphere for three hours at room temperature. After reaction completion, the reaction mixture was poured into water and extracted with ethyl acetate (2x20 mL). The combined organic layer was divided, dried over magnesium sulfate, filtered and concentrated under vacuum, giving the crude product 8, which was used for the next step without purification (365 mg).
Characterization: UPLC/MS Rt: 2.40 min (gradient 2), MS (ESI) m/z: 631.2 [M+H]+ .[M+H]+ Calculated: 631.2 for C41H37O8.
Step 4. Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3- hydroxypropoxy)-4H-chromen-4-one (compound 9, Scheme 2).
Compound 9 was prepared following general procedure D using: compound 8 (365 mg, 0.58 mmol), Pd/C (72 mg), Et3SiH (2.2 mL, 10.5 mmol) in a 1:1 mixture of MeOH/DCM (14 mL). Purification by silica (elution by gradient from 100 to 40/60 Cyclohexane/EtOAc) gave the pure compound 9 (33 mg, 15% yield in two steps).
Characterization: Rt: 1.40 min (gradient 1), MS (ESI) m/z: 361.1 [M+H]+ .[M+H]+ Calculated for C19H19O7: 361.1.
1H-NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.4, 2.2 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 6.18 (d, J = 2.1 Hz, 1H), 4.01 (t, J = 6.7 Hz, 2H), 3.49 (t, J = 6.4 Hz, 2H), 1.81 (p, J = 6.5 Hz, 2H). 13C-NMR (101 MHz, DMSO-d6) 5 178.04, 164.12, 161.29, 156.37,
155.95, 148.62, 145.18, 136.75, 120.96, 120.78, 115.64, 115.51,
104.17, 98.54, 93.57, 69.72, 57.71, 32.91.
Reference is now made to Scheme 3.
Synthesis of N-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-2- carboxamide (compound 13, Scheme 3).
NaOEt (210 mg, 3 mmol) was dissolved in absolute EtOH 4 mL). A mixture of diethyl oxalate (310 mg, 2.1 mmol) and 2-hydroxy-6- methoxyacetophenone lc (100 mg, 0.6 mmol) in absolute EtOH (2 mL)
was slowly added to the NaOEt solution. The solution was reflux- stirred for 2 hours until complete consumption of starting material. The mixture was then allowed to cool to room temperature and neutralized with acq. HCl (2 M). The mixture was extracted with EtOAc (3 x 5 mL), the collected organic layer was dried over Na2SO4, filtered and concentrated under vacuum. Purification by silica (elution by gradient from 100:0 to 75:25 Cyclohexane/EtOAc) gave the pure title compound 10 (120 mg, 79%).
Characterization: UPLC/MS Rt: 1.50 min (gradient 1), MS (ESI) m/z 249.0, [M+H]+ . [M+H]+ calculated for C17H15O5: 249.3. 1H NMR (400
MHz, CDCI3) δ 7.40 (dd, J = 8.4, 8.4 Hz, 1H), 6.60 - 6.58 (m, 2H), 6.42 (d, J = 8.4 Hz, 1H), 4. 38 (q, J = 7.2 Hz, 2H), 3.93 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H).
Step 2. Synthesis of 5-methoxy-4-oxo-4H-chromen-2-carboxylic acid (compound 11).
K2CO3 (100 mg, 0.60 mmol) was added to a solution of intermediate 10 (100 mg, 0.40 mmol) in a 3:1 mixture of THF/EtOH (4 mL). The reaction mixture was stirred for 6 h at 50°C until complete consumption of the starting material, then acq. HC1 (2 M) was added up to reaching pH=5, and the mixture was extracted with EtOAc (3x4 mL). The collected organic layers were dried over Na2SO4, filtered and concentrated under vacuum to give the pure compound 11 (70 mg, 79% yield).
Characterization: UPLC/MS Rt: 0.80 min (gradient 1), MS (ESI) m/z 220.9, [M+H]+. [M+H]+ calculated for C11H9O5: 221.2.
NMR (400 MHz, DMSO-d6) δ 7.72 (dd, J = 8.4, 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 3.86 (s, 3H).
Step 3. Synthesis of N-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4H- chromen-2-carboxamide (compound 12).
HATU (170 mg, 0.43 mmol) and DIPEA (0.23 mL, 1.3 mmol) were sequentially added to a solution of intermediate 11 (60 mg, 0.29 mmol) in a 3:1 mixture of DMF/DCM (4 mL) under argon. The reaction mixture was stirred at room temperature for 15 minutes, after that 3,4-dimethoxyaniline (44 mg, 0.29 mmol) was added and the reaction mixture was stirred for another 4 hours until complete consumption of the starting material. Water (1 mL) and acq. HCl (2 M) were added to reach pH=7, the mixture was extracted with CH2CI2 (3 x 3 mL), the collected organic layers were dried over Na2SO4, filtered and concentrated under vacuum. Purification by silica (elution by gradient from 100:0 to 55:45 DCM/EtOAc) gave the pure title compound 12 (92 mg, 90%).
Characterization: UPLC/MS Rt: 1.66 min (gradient 1), MS (ESI) m/z 356.0, [M+H]+ . [M+H]+ calculated for C19H18NO6: 356.3.
NMR (400 MHz, DMSO-d6) δ 7.78 (dd, J = 8.4, 8.4 Hz, 1H), 7.44 (d, J = 2.4 Hz, 1H), 7.36 (dd, J = 8.6, 2.4 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H),
7.05 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.76 (s, 1H),
3.88 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H).
Step 4, Synthesis of N-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H- chromen-2-carboxamide (compound 13).
Compound 13 was prepared following general procedure C, method A using: intermediate 12 (45 mg, 0.13 mmol), BBrs (1 M in DCM) (0.59 mL, 0.59 mmol) in anhydrous CH2CI2 (2.6 mL). The crude product was purified by silica (elution by gradient from 100:0 to 98:2 DCM/MeOH) to give product 13 (0.016 g, 40% yield).
Characterization: UPLC/MS Rt: 1.65 min (gradient 1), m/z 312.0,
[M-H]-. [M-H]-. calculated for C16H10NO6: 312.3. 1H NMR (400 MHz,
DMSO-d6) δ 12.30 (bs, 1H), 10.48 (bs, 1H), 9.01 (bs, 1H), 7.77 (dd, J = 8.4, 8.4 Hz, 1H), 7.30 (d, J = 2.5 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.03 (dd, J = 8.5, 2.5 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H).
Activity measurement
Pol η activity was assessed by quantification of the final product of DNA synthesized with the enzyme in the presence of all four dNTPs/nucleotides. The double strand of DNA used in the reaction was created by annealing an IRD700-labeled primer to a template strand. A mixture of DNA template and Pol η was placed on ice in an assay buffer solution and then added in test tubes containing
the inhibitors or DMSO (as vehicle; the final concentration in the assay is 1%). The reaction was started with the addition of 5 mM Mg2+ and immediately transferred to 37°C. After 60 minutes of incubation, the reaction was stopped with the addition of 5X loading buffer for the sample and incubation for 5 minutes at 70°C. The Pol η extension products were then separated by denaturing electrophoresis (15% polyacrylamide/tbe/urea gel; BioRad) and scanned using the ChemiDoc imaging system (BioRad Laboratories).
Cell viability assay
Compound 9 was evaluated for the inherent antiproliferative activity thereof, individually and together with cisplatin on the cancer cell lines A549, A375 and OVCAR3. The antiproliferative activity of compound 9 was evaluated using the MTT cell viability assay. To assess antiproliferative activity, the cells were seeded at a density of 5000 cells/well (A549), 3000 cells/well (A375) and 10000 cells/well (OVCAR3). After 24 hours, the cells were first treated with Cisplatin (0.4-50 μM) alone and compound 9 (0.046-100 μM), then with Cisplatin (0.4-50 μM) with compound 9 at 50 μM, 75 μM and 100 μM for 48 hours. The MTT solution was added to a final concentration of 0.5 mg/ml and the cells were further incubated for 4 hours. The insoluble formazan crystals were solubilized by the addition of a 10% 0.01 N SDS/HC1 solution and the absorbance measured at 570 nm (reference 690 nm) in a plate reader (Tecan Spark). The inhibition curves were 8 serial dilutions in triplicate in each case, and the results were analyzed as
sigmoidal dose-response curves using GraphPad Prism software. The values are reported as meaniSD of three experiments.
a The concentration of compound 9 is 100 μM b The concentration of compound 9 is 50 μM c The concentration of compound 9 is 75 μM
From the above, the advantages linked to the present invention will be immediately apparent to those skilled in the art.
Firstly, the compounds described have been shown to be very active in inhibiting human polymerase eta (Pol η) representing a potential tool for the therapy of chemo-resistant tumors in combination with current therapies, for example comprising the use of Cis platinum.
The data obtained show the effectiveness in inhibiting the proliferation of cancer cells and the low cell toxicity.
Furthermore, data also show that the stability and solubility values are favorable for medical use.
The main structure and substructures define scaffolds which allow a good chemical diversity, allowing many compounds with similar structure to be investigated.
In addition to this, the compounds described are referred to as small molecules, thus being molecules of small size capable of being easily synthesized.
It is worth to emphasize that the present invention contemplates already known compounds, and therefore it applies to the so-called "repurposing" of drugs, thus making the evaluations
of activity and toxicity of a possible drug for the new identified disease faster.
Claims
R1, R2, R3, R4, R5 and R6 are, independently of each other, -H, -OH, -R7, -X, -OR7, —R7(X)n, -NO2, -NH2, -NHR7, where
R7 is a linear or branched C1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO2, -NH2, -NHR8, where R8 is a linear or branched C1-4 alkyl, or where
R1, R2, R3, R4 and R7 are as described above and R5 and R6 form, together with the benzene ring to which they are bound, a (2,2- difluorobenzo[d][1,3]dioxol cycle:
X is halogen in any position of the chain, n=1-4 on the entire chain and preferably 1-3 and
A is a single bond for medical use in treating diseases or disorders represented by primary and/or metastatic neoplasms, which have developed resistance after previous treatment with chemotherapeutic compounds.
3. Compounds according to claim 1 or 2 for medical use, wherein said neoplasms are represented by: ovarian tumor, breast tumor, pancreatic tumor, lung tumor, gastric adenocarcinoma, mucosa-derived squamous cell carcinoma of the neck.
4. Compounds for medical use according to any one of the preceding claims 3 to 6, wherein said medical use is in combination with chemotherapeutic compounds.
5. Compounds for medical use according to the preceding claim, wherein said chemotherapeutic compounds are represented by nucleoside analogues or alkylating agents derived from platinum.
R1, R2, R4, R5 and R6 are, independently of each other,
-H, -R7, -x, -OH, -OR7, -R7(X)n, -NO2, -NH2, -NHR7, wherein
R7 is a linear or branched C1-4 alkyl optionally substituted with one or more groups selected from -OH, -X, -NO2, -NH2, -NHR8, where R8 is a linear or branched C1-4 alkyl,
R3 is H,
X is halogen in any position of the chain, n=1-4 on the entire chain and preferably 1-3 and
7. Compounds of formula (I) according to the preceding claim represented by the following compounds:
8. A formulation comprising one of the compounds according to claim 6 or 7.
9. A formulation according to the preceding claim, for oral, nasal, subcutaneous or intramuscular administration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102022000007988A IT202200007988A1 (en) | 2022-04-22 | 2022-04-22 | 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation |
IT102022000007988 | 2022-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023203535A1 true WO2023203535A1 (en) | 2023-10-26 |
Family
ID=82608476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/054098 WO2023203535A1 (en) | 2022-04-22 | 2023-04-21 | 4-chromone derivatives as n-polymerase inhibitors for use in the treatment platinum resistant metastatic neoplasm |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT202200007988A1 (en) |
WO (1) | WO2023203535A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076863A1 (en) * | 2005-01-20 | 2006-07-27 | Shanghai Gloriayx Biopharmaceuticals Co., Ltd | The synergistically pharmaceutical composition for inhibiting tumor |
WO2011099978A1 (en) * | 2010-02-12 | 2011-08-18 | N30 Pharmaceuticals, Llc | Chromone inhibitors of s-nitrosoglutathione reductase |
WO2019008537A1 (en) * | 2017-07-05 | 2019-01-10 | Vera Salus Ricerca S.R.L. | Medical compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
PT3411036T (en) | 2016-02-04 | 2022-02-21 | Pharmaengine Inc | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
-
2022
- 2022-04-22 IT IT102022000007988A patent/IT202200007988A1/en unknown
-
2023
- 2023-04-21 WO PCT/IB2023/054098 patent/WO2023203535A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076863A1 (en) * | 2005-01-20 | 2006-07-27 | Shanghai Gloriayx Biopharmaceuticals Co., Ltd | The synergistically pharmaceutical composition for inhibiting tumor |
WO2011099978A1 (en) * | 2010-02-12 | 2011-08-18 | N30 Pharmaceuticals, Llc | Chromone inhibitors of s-nitrosoglutathione reductase |
WO2019008537A1 (en) * | 2017-07-05 | 2019-01-10 | Vera Salus Ricerca S.R.L. | Medical compounds |
Non-Patent Citations (5)
Title |
---|
CATANZARO DANIELA ET AL: "Cell Cycle Control by Natural Phenols in Cisplatin-Resistant Cell Lines", NATURAL PRODUCT COMMUNICATIONS, vol. 9, no. 10, 1 October 2014 (2014-10-01), US, XP093003570, ISSN: 1934-578X, DOI: 10.1177/1934578X1400901015 * |
LUO HAITAO ET AL: "Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 11 May 2010 (2010-05-11), pages 16, XP021077239, ISSN: 1475-2867, DOI: 10.1186/1475-2867-10-16 * |
PAPACHRISTOU FOTINI ET AL: "Differential effects of cisplatin combined with the flavonoid apigenin on HepG2, Hep3B, and Huh7 liver cancer cell lines", MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, vol. 866, 1 June 2021 (2021-06-01), NL, pages 503352, XP093003646, ISSN: 1383-5718, DOI: 10.1016/j.mrgentox.2021.503352 * |
SUN LEI ET AL: "Synthesis, characterization and antioxidant activity of quercetin derivatives", SYNTHETIC COMMUNICATIONS, vol. 51, no. 19, 23 August 2021 (2021-08-23), US, pages 2944 - 2953, XP055943921, ISSN: 0039-7911, DOI: 10.1080/00397911.2021.1942059 * |
ZHANG YU ET AL: "Flavonoids from Chinese bayberry leaves induced apoptosis and G1 cell cycle arrest via Erk pathway in ovarian cancer cells", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 147, 1 March 2018 (2018-03-01), AMSTERDAM, NL, pages 218 - 226, XP093003652, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.01.084 * |
Also Published As
Publication number | Publication date |
---|---|
IT202200007988A1 (en) | 2023-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clark et al. | Synthesis and antihypertensive activity of 4'-substituted spiro [4H-3, 1-benzoxazine-4, 4'-piperidin]-2 (1H)-ones | |
KR100991920B1 (en) | Inhibitors Of Cyclin-Dependent Kinases And Their Use | |
JPH07228558A (en) | Stilbene derivative and carcinostatic agent containing the same | |
JPH0826037B2 (en) | Derivatives of physiologically active substance K-252 | |
EP2844657A1 (en) | Therapeutic compounds | |
JPS61155358A (en) | Diallylbutyric acid derivative and production thereof | |
US6071930A (en) | Method for treating tumors using 2-aryl-naphthyridin-4-ones | |
JP5290996B2 (en) | Tetrahydroquinazoline compounds and their use in preparing drugs for treating and preventing viral diseases | |
CN111087408B (en) | Macrocyclic IDH2 mutant inhibitor and medical application thereof | |
CN111434654A (en) | Triazole hexanone biaryl (hetero) ring derivative and preparation method and application thereof | |
WO2023203535A1 (en) | 4-chromone derivatives as n-polymerase inhibitors for use in the treatment platinum resistant metastatic neoplasm | |
EP0768311A1 (en) | Pyrrolocarbazole derivatives | |
JP2001515900A (en) | Antiviral drugs | |
CN110105356B (en) | Azaindole compound and preparation method and application thereof | |
Ji et al. | Antitumor agents. 1771. Design, syntheses, and biological evaluation of novel etoposide analogs bearing pyrrolecarboxamidino group as DNA topoisomerase II inhibitors | |
KR101455452B1 (en) | New G-quadruplex DNA Binders, process for preparation thereof and the use of the same | |
JPH0560478B2 (en) | ||
CN113166148A (en) | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors | |
CN110590681A (en) | Novel quinazoline ketone compound and preparation method and application thereof | |
CN111617085B (en) | Targeted HDAC inhibitor and application thereof in antitumor therapeutic drugs | |
WO2021200824A1 (en) | Novel xanthenone derivative | |
KR101926612B1 (en) | Anti-inflammatory pharmaceutical compounds containing 2,5-diaryloxazole compounds | |
CN108948003B (en) | Preparation and application of pyrazino [2,3-c ] quinoline-2 (1H) -ketone compound as mTOR inhibitor | |
EP0168288B1 (en) | Aminomethyl-6-furo-[3,4-c]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
US9873699B1 (en) | Anti-cancer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23725417 Country of ref document: EP Kind code of ref document: A1 |